NASDAQ: ABVC - ABVC BioPharma, Inc.

Rentabilité sur six mois: +63.76%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions ABVC BioPharma, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise ABVC BioPharma, Inc.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.

plus de détails
The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2017-10-11
ISIN US00091F1066
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.abvcpharma.com
Цена ао 0.705
Changement de prix par jour: 0% (0.8953)
Changement de prix par semaine: -8.64% (0.98)
Changement de prix par mois: +37.61% (0.6506)
Changement de prix sur 3 mois: +64.28% (0.545)
Changement de prix sur six mois: +63.76% (0.5467)
Changement de prix par an: -12.23% (1.02)
Evolution du prix sur 3 ans: -64.89% (2.55)
Evolution du prix sur 5 ans: -79.51% (4.37)
Evolution des prix depuis le début de l'année: +77.32% (0.5049)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 34.42 1
P/BV 0.6113 10
P/E 0 0
EV/EBITDA -0.8525 0
Total: 4.25

Efficacité

Nom Signification Grade
ROA, % -70.37 0
ROE, % -118.96 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.2994 10
Total: 9.8

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -78.29 0
Rentabilité Ebitda, % 146.44 10
Rentabilité EPS, % 7.8 1
Total: 5.2
Plus de détails

Établissements Volume Partager, %
Renaissance Technologies, LLC 36100 0.34
Vanguard Group Inc 27247 0.26
Citadel Advisors Llc 27158 0.26
Geode Capital Management, LLC 19480 0.18
Tower Research Capital LLC (TRC) 578 0.01
Spotlight Asset Group, Inc. 100 0
Royal Bank of Canada 37 0
Wells Fargo & Company 20 0



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Eugene Jiang Chairman & Chief Business Officer 200k 1986 (39 années)
Dr. Tsung-Shann Jiang EMBA, Ph.D. Chief Scientific Officer, Chief Strategy Officer & Director 200k 1954 (71 année)
Dr. Uttam Yashwant Patil Ph.D. CEO & Interim CFO N/A 1986 (39 années)

Adresse: United States, Fremont. CA, 44370 Old Warm Springs Boulevard - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.abvcpharma.com